Ignite Creation Date:
2025-12-24 @ 4:12 PM
Ignite Modification Date:
2026-03-01 @ 12:05 PM
Study NCT ID:
NCT01663766
Status:
TERMINATED
Last Update Posted:
2021-08-19
First Post:
2012-08-07
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase I Study of Milatuzumab for Graft Versus Host Disease
Sponsor:
Gilead Sciences
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | GVHD (Acute or Chronic) | View |
| None | Acute Myeloid or Lymphoblastic Leukemia (AML or ALL) | View |
| None | Myelodysplastic Syndrome | View |
| None | Chronic Myelogenous Leukemia (CML) | View |
| None | Multiple Myeloma (MM) | View |
| None | Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell) | View |
| None | Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL or SLL) | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | GVHD (acute or chronic) | View |
| None | acute myeloid or lymphoblastic leukemia (AML or ALL) | View |
| None | myelodysplastic syndrome | View |
| None | Chronic myelogenous leukemia (CML) | View |
| None | Multiple Myeloma (MM) | View |
| None | Non-Hodgekin lymphoma (NHL-both follicular & diffuse large cell) | View |
| None | Chronic lymphocytic leukemia or small lymphocytic leukemia (CLL or SLL) | View |